Probing the cons and pros of lectin-induced immunomodulation: Case studies for the mistletoe lectin and galectin-1

Biochimie

Volumn 83, Issue 7, 2001, Pages 659-666

  Gabius, H J ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Apoptosis; Cytokines; Galectin; Immunomodulation; Lectin; Mistletoe; T cell disease

Indexed keywords

CD7 ANTIGEN; CYTOKINE; GALACTOSIDE; GALECTIN; GALECTIN 1; GLYCAN; LECTIN; LIGAND; UNCLASSIFIED DRUG; VISCUM ALBUM LECTIN;

APOPTOSIS; AUTOIMMUNE DISEASE; BINDING AFFINITY; CASE STUDY; CELL ACTIVITY; CELL STRUCTURE; CELL SURFACE; CHEMICAL CARCINOGENESIS; DISEASE COURSE; DRUG EFFECT; EXTRACELLULAR SPACE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INFLAMMATION; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; NONHUMAN; REGULATORY MECHANISM; REVIEW; SENSOR; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH2 CELL; TRANSPLANTATION; TUMOR; TUMOR CELL CULTURE; TUMOR GROWTH;

EID: 0034850491     PISSN: 03009084     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-9084(01)01311-6     Document Type: Review

References (115)

1. Preface
2. Analysis of growth of lectin literature: 1983-1986
3. Glycoproteins now and then: A personal account
4. Medicinal chemistry based on the sugar code: Fundamentals of lectinology and experimental strategies with lectins as targets
5. The information-storing potential of the sugar code
6. Biological information transfer beyond the genetic code: The sugar code
7. Glycomics, coming of age!
8. The how and why of protein-carbohydrate interaction: A primer to the theoretical concept and a guide to application in drug design
9. Lectins: Carbohydrate-specific proteins that mediate cellular recognition
10. Lectins as mitogens
11. Plant lectins in immunology, cytology and hematology: A bibliography and projects for development
12. Lectins in immunology
13. The role of cell surface lectin-carbohydrate interactions in cellular recognition, cooperation, and regulation
14. Lectin-carbohydrate interaction in the immune system
15. Animal lectins
16. Animal lectins as cell adhesion molecules
17. C-type lectins and galectins mediate innate and adaptive immune functions: Their roles in the complement activation pathway
18. Unproven methods in cancer treatment
19. Mistletoe treatment for cancer. Review of controlled trials in humans
20. Mistelextrakte in der Krebstherapie
21. Unkonventionelle - Alternative therapieverfahren in der palliativen urologischen onkologie
22. Zum nutzen von mistelextrakten (iscador u. a.) bei krebsn
23. Mistel: Gestaltung eines Mythos
24. Anthroposophische arzneimittel
25. Mechanism of action of ricin and related toxins on the inactivation of eukaryotic ribosomes
26. Ribosome-inactivating proteins from plants
27. Ligand-binding characteristics of the major mistletoe lectin
28. Further refinement of the description of the ligand-binding characteristics for the galactoside-binding mistletoe lectin, a plant agglutinin with immunomodulatory potency
29. Die problematik der sogenannten unkonventionellen krebstherapie
30. Evidence for stimulation of tumor proliferation in cell lines and histotypic cultures by clinically relevant low doses of the galactoside-binding mistletoe lectin, a component of proprietary extracts
31. Plant lectins - More than just tools for glycoscientists: Occurrence, structure and possible functions of plant lectins
32. Studies on the tumor-inhibiting efficacy of Iscador® in experimental animal tumors
33. Prevention of 20-methylcholanthrene-induced sarcoma by a mistletoe extract, Iscador®
34. Antitumoral effects of an intravesically applied aqueous mistletoe extract on urinary bladder carcinoma MB49 in mice
35. Phase I study of the plant protein ricin
36. Modulatory potency of the β-galactoside-specific lectin from mistletoe extract (Iscador®) on the host defense system in vivo in rabbits and patients
37. Increased secretion of tumor necrosis factor-α, interleukin-1, and interleukin-6 by human mononuclear cells exposed to the β-galactoside-specific lectin from clinically applied mistletoe extract
38. The galactoside-specific lectin from mistletoe as biological response modifier
39. The immunomodulatory β-galactoside-specific lectin from mistletoe: Partial sequence analysis, cell and tissue binding and impact on intracellular biosignaling of monocytic leukemia cells
40. Multivalent lectin-carbohydrate cross-linking interactions
41. Signaling pathways for transduction of the initial message of the glycocode into cellular responses
42. Comparative cross-linking activities of lactose-specific plant and animal lectins and a natural lactose-binding immunoglobulin G fraction from human serum with asialofetuin
43. A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells
44. Stimulation of cytokine production via a special standardized mistletoe preparation in an in vitro human skin bioassay
45. Mistletoe lectins I, II and III induce the production of cytokines by cultured human monocytes
46. Effects of mistletoe lectin I on human blood cell lines and peripheral blood cells. Cytotoxicity, apoptosis and induction of cytokines
47. Effect of a recombinant lectin, Viscum album agglutinin, on the secretion of interleukin-12 in cultured human peripheral blood mononuclear cells and on NK-cell-mediated cytotoxicity of rat splenocytes in vitro and in vivo
48. The host-tumor immune conflict: From immunosuppression to resistance and destruction
49. Interleukin-6 in progression of human solid tumors: Transitional changes in the regulation of cell growth, apoptosis and angiogenesis
50. Tumor immunology: The glass is half full
51. Expression of an exogenous interleukin 6 gene in human Epstein Barr virus B cells confers growth advantage and in vivo tumorigenicity
52. Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice
53. Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice
54. Interleukin 6 is essential for in vivo development of B lineage neoplasms
55. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice
56. Human interleukin-6 is in vivo an autocrine growth factor for human herpes virus-8-infected malignant B lymphocytes
57. Effect of interleukin-1β on metastasis formation in different tumor systems
58. Effect of ultraviolet-inducible cytokines on melanoma growth in vivo: Stimulation of melanoma growth by interleukin-1 and -6
59. Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis
60. Endogenous interleukin 6 can function as an in vivo growth-stimulatory factor for advanced-stage human melanoma cells
61. Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression
62. Growth stimulation of non-small cell lung cancer xenografts by granulocyte-macrophage colony-stimulating factor (GM-CSF)
63. Effect of IL-6 overexpression on the metastatic potential of rat hepatocellular carcinoma cells
64. Role of endogenous tumor necrosis factor α and interleukin 1 for experimental tumor growth and the development of cancer cachexia
65. Expression of the interleukin 6 receptor in primary renal cell carcinoma
66. Tumour stimulating effects of recombinant human interleukin-6
67. Expression of interleukin-1β in human breast carcinoma
68. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue
69. Lack of an antitumoral effect of immunomodulatory galactoside-specific mistletoe lectin on N-methyl-N-nitrosourea-induced urinary bladder carcinogenesis in rats
70. Inability of galactoside-specific mistletoe lectin to inhibit N-methyl-N-nitrosourea-initiated tumor development in the urinary bladder of rats and to induce a local cellular immune response after long-term administration
71. Long-term administration of galactoside-specific mistletoe lectin in an animal model: No protection against N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder carcinogenesis in rats and no induction of a relevant local cellular immune response
72. Immunotherapy of C3H/HeJ mammary adenocarcinoma with interleukin-2, mistletoe lectin or their combination: Effects on tumor growth, capillary leakage and NO production
73. Letter to the editor
74. Subcutaneous appearance of a centrocytic non-Hodgkin lymphoma at the site of injection of a mistletoe preparation
75. Zu Berichten über unerwünschte Arzneimittelwirkungen nach Behandlung mit Mistelextrakt-haltigen und Organ-/Enzympräparaten bei Tumorerkrankungen
76. Ungewöhnliche Immunerkrankungen durch Pflanzenextrakte (Echinacea, Mistel): Akute Sarkoidose
77. Lectin structure
78. Lectins
79. The 2.15 Å crystal structure of CG-16, the developmentally regulated homodimeric chicken galectin
80. NMR-based, molecular dynamics- and random walk molecular mechanics-supported study of conformational aspects of a carbohydrate ligand (Galβ1-2Galβ1-R) for an animal galectin in the free and in the bound state
81. Conformer selection and differential restriction of ligand mobility by a plant lectin
82. A new combined computational and NMR-spectroscopical strategy for the identification of additional conformational constraints of the bound ligand in an aprotic solvent
83. Prevention and therapy with electrolectin of experimental autoimmune myasthenia gravis in rabbits
84. Recombinant human β-galactoside binding lectin suppresses clinical and histological signs of experimental autoimmune encephalomyelitis
85. Galectin-1 exerts immunomodulatory and protective effects on concanavalin A-induced hepatitis in mice
86. Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis
87. Isolation of a cDNA clone, encoding a human β-galactoside binding protein, overexpressed during glucocorticoid-induced cell death
88. Induction of T lymphocyte apoptosis: A novel function for galectin-1
89. Galectin-1 gene expression and methylation state in human T leukemia cell lines
90. CD7 delivers a pro-apoptotic signal during galectin-1-induced T cell death
91. Expression of the endogenous 14-kDa β-galactoside-binding lectin galectin in normal human skin
92. Concepts of tumor lectinology
93. Galectins in tumor cells
94. Induction of differentiation and apoptosis in the prostate cancer cell line LNCaP by sodium butyrate and galectin-1
95. Specific inhibition of T-cell adhesion to extracellular matrix and proinflammatory cytokine secretion by human recombinant galectin-1
96. Evidence of a role for galectin-1 in acute inflammation
97. A budesonide-mediated increase in galectin-1 expression in nasal polyps results in a decreased level of eosinophil migration
98. Galectin-3 down-regulates IL-5 gene expression on different cell types
99. Interaction between galectin-3 and FcγRII induces down-regulation of IL-5 gene: Implication of the promoter sequence IL-5REIII
100. Expression of galectin-3 modulates T-cell growth and apoptosis
101. Galectin-3: A novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family
102. Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis
103. Requirement of divalent galactoside-binding activity of ecalectin/galectin-9 for eosinophil chemoattraction
104. Efficacy of galectins in the amelioration of nephrotoxic serum nephritis in Wistar Kyoto rats
105. Identification and characterization of galectin-9, a novel β-galactoside-binding mammalian lectin
106. Gene expression of galectin-9/ecalectin, a potent eosinophil chemoattractant, and/or the insertional isoform in human colorectal carcinoma cell lines and detection of frameshift mutations for protein sequence truncations in the second functional lectin domain
107. Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures
108. The galactosyltransferases
109. Glycobiology
110. Glycocoding as an information management system in embryonic development
111. On the biological role of glycoproteins
112. Adhesins as lectins: Specificity and role in infection
113. Endogenous lectins as targets for drug delivery
114. Lectins: From obscurity into the limelight